Sana Biotechnology, Inc. (SANA) Stock Analysis

Sana (SANA) Upgraded to Buy: Here's What You Should Know

Wed, July 15, 2026 at 4:00 PM UTC 4 min read

Sana (SANA) has been upgraded to a "Buy" rating by analysts, reflecting increased confidence in the company's growth potential and market position. This upgrade is significant for investors as it suggests a favorable outlook for SANA's stock performance, potentially leading to higher returns. Investors may want to consider this positive sentiment when evaluating their portfolios.

Read full article →

Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs

Tue, May 12, 2026 at 8:05 PM UTC 3 min read

Sana Biotechnology has presented promising preclinical data for its in vivo CAR T cell therapy, SG293 Surrogate, showcasing effective cell-specific delivery, robust CAR T cell generation, and significant B cell depletion in non-human primates. This advancement highlights the potential of Sana's technology to enhance targeted cancer therapies, which could lead to improved treatment outcomes. For investors, these results may signal a step forward in the company's pipeline and bolster confidence in its future clinical developments.

Read full article →